← Back to Search

Docetaxel+IMRT for Prostate Cancer

Q: What evidence exists to suggest that the combination of Docetaxel and IMRT is effective?

Currently, 320 trials that investigate Docetaxel+IMRT are underway with 126 at the last stage of development. The majority of these studies occur in Fuzhou, Fujian; however, 22389 medical centres around the world are conducting clinical trial research on this combo therapy.

Q: Am I able to partake in this medical experiment?

To be eligible for this medical trial, applicants must have <a href="https://www.withpower.com/clinical-trials/prostate-cancer">prostate cancer</a> and lie within the ages of 18 to 100. Currently, 25 patients are being accepted.

Q: Does the trial include geriatric participants?

This clinical trial is recruiting patients between 18 and 100 years old. Those younger than 18 or older than 65 can take part in 88 and 1627 studies respectively.

Q: Is enrollment in this experiment available to participants at the present moment?

Records on clinicaltrials.gov verify that this trial has concluded its recruitment period, though it was initially advertised in late 2006 and last edited almost a year ago. Nonetheless, there are an abundance of other studies actively seeking participants at the moment - 1641 to be exact.

Q: How many individuals are participating in this clinical experiment?

This clinical investigation is no longer recruiting patients. Initially uploaded on January 31st 2006, the last edit was made April 19th 2022. For those seeking other medical trials there are 1,321 investigations into <a href="https://www.withpower.com/clinical-trials/prostate-cancer">prostate cancer</a> and 320 looking for people to trial Docetaxel+IMRT therapies.

Q: What are the primary applications of Docetaxel+IMRT?

Docetaxel+IMRT is a viable treatment option for malignant neoplasms, advance directives, and <a href="https://www.withpower.com/clinical-trials/sarcoma">sarcoma</a>.

Phase 1 & 2

Waitlist Available

Led By Mark Garzotto, MD

Research Sponsored by OHSU Knight Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3, 6, 9, 12 months and annually, up to 5 years

Awards & highlights

Study Summary

This trial is studying docetaxel and radiation therapy before surgery in treating patients with high-risk localized prostate cancer.

Eligible Conditions

Prostate Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3, 6, 9, 12 months and annually, up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3, 6, 9, 12 months and annually, up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3, 6, 9, 12 months and annually, up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Maximum Tolerated Dose (MTD)

Pathologic Response Rate at the Phase II Dose

Secondary outcome measures

Clinical Progression-free Rate as Determined by <0.1ng PSA Results

Clinical Response to Treatment as Measured by Urologic Examination

Efficacy Assessed Using Health-Related Quality of Life by Expanded Prostate Cancer Index Composite and Urinary Symptom Scores by American Urological Association's Measures

+3 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: Phase II MTD DoseExperimental Treatment1 Intervention

Phase II with no phase I dose-limiting toxicities=Docetaxel IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)

Group II: Phase I Dose 1-4Experimental Treatment2 Interventions

Group 1=radiation only; Group 2=Docetaxel IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=Docetaxel IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=Docetaxel IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

OHSU Knight Cancer InstituteLead Sponsor

230 Previous Clinical Trials

2,090,701 Total Patients Enrolled

26 Trials studying Prostate Cancer

2,408 Patients Enrolled for Prostate Cancer

Mark Garzotto, MDPrincipal InvestigatorOHSU Knight Cancer Institute

5 Previous Clinical Trials

1,738 Total Patients Enrolled

4 Trials studying Prostate Cancer

1,724 Patients Enrolled for Prostate Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What evidence exists to suggest that the combination of Docetaxel and IMRT is effective?

"Currently, 320 trials that investigate Docetaxel+IMRT are underway with 126 at the last stage of development. The majority of these studies occur in Fuzhou, Fujian; however, 22389 medical centres around the world are conducting clinical trial research on this combo therapy."

Answered by AI

Am I able to partake in this medical experiment?

"To be eligible for this medical trial, applicants must have prostate cancer and lie within the ages of 18 to 100. Currently, 25 patients are being accepted."

Answered by AI

Does the trial include geriatric participants?

"This clinical trial is recruiting patients between 18 and 100 years old. Those younger than 18 or older than 65 can take part in 88 and 1627 studies respectively."

Answered by AI

Is enrollment in this experiment available to participants at the present moment?

"Records on clinicaltrials.gov verify that this trial has concluded its recruitment period, though it was initially advertised in late 2006 and last edited almost a year ago. Nonetheless, there are an abundance of other studies actively seeking participants at the moment - 1641 to be exact."

Answered by AI

How many individuals are participating in this clinical experiment?

"This clinical investigation is no longer recruiting patients. Initially uploaded on January 31st 2006, the last edit was made April 19th 2022. For those seeking other medical trials there are 1,321 investigations into prostate cancer and 320 looking for people to trial Docetaxel+IMRT therapies."

Answered by AI